{"": [95, 1796, 0], "1.1. Spike: Main Features and Functions": [3973, 7860, 0], "1.2.1. Cytokine Storm Syndrome": [10084, 11289, 0], "1.2.2. Gal-3 as a Mediator of Lung Fibrosis": [11290, 13134, 0], "1.2. Galectin-3: Main Features and Functions": [7861, 13134, 1], "1.3. Sars-Cov2 Attachment: Implications of the Galectin-Like S1-NTD": [13135, 18663, 0], "1. Introduction": [1797, 18663, 1], "2.1. Data Set Collection and Ligand Database Preparation": [18690, 19648, 0], "2.2. Preparation of the Protein ": [19649, 22309, 0], "2.3. Binding Sites Locater (Site Finder)": [22310, 25449, 0], "2.4. Molecular Docking": [25450, 27076, 0], "2.5. Regression Analysis": [27077, 28115, 0], "2.6. Protein\u2013Ligand Interaction Fingerprint (PLIF)": [28116, 28546, 0], "2.7. Toxicity Risk": [28547, 29455, 0], "2. Materials and Methods": [18664, 29455, 1], "3.1. Regression Analysis on Galectin-3": [29714, 30550, 0], "3.2. Molecular Docking Calculations": [30551, 33039, 0], "3.3. Galectin-3 Protein Interactions with Top Ranked Inhibitors": [33040, 35806, 0], "3.4. Spike Protein Interactions with Top Ranked Inhibitors": [35807, 38895, 0], "3.5. Protein Ligand Interaction Fingerprints (PLIF) Analysis": [38896, 40130, 0], "3.6. Toxicity Analysis": [40131, 41091, 0], "3.7. Coronavirus Variants": [41092, 43796, 0], "3. Results": [29456, 43796, 1], "4. Discussion": [43797, 49518, 0], "5. Conclusions": [49519, 53569, 0]}